Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Dec;39(12):2801–2802. doi: 10.1128/aac.39.12.2801

Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia.

R Bohte 1, H Mattie 1, P J van den Broek 1
PMCID: PMC163034  PMID: 8593024

Abstract

After an oral dose of 500 mg of azithromycin in patients with community-acquired pneumonia, their serum concentrations ranged between 0.06 and 0.25 mg/liter during the first 12 hours; the calculated percentages of unbound drug varied between 45 and 86%. This study shows that in these patients, the total levels of azithromycin in serum are lower than those expected and that the percentage of bound drug is clinically irrelevant.

Full Text

The Full Text of this article is available as a PDF (152.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bins J. W., Mattie H. Saturation of the tubular excretion of beta-lactam antibiotics. Br J Clin Pharmacol. 1988 Jan;25(1):41–50. doi: 10.1111/j.1365-2125.1988.tb03280.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Girard A. E., Girard D., English A. R., Gootz T. D., Cimochowski C. R., Faiella J. A., Haskell S. L., Retsema J. A. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother. 1987 Dec;31(12):1948–1954. doi: 10.1128/aac.31.12.1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hoogeterp J. J., Mattie H., van Furth R. Activity of erythromycin and clindamycin in an experimental Staphylococcus aureus infection in normal and granulocytopenic mice. A comparative in vivo and in vitro study. Scand J Infect Dis. 1993;25(1):123–132. doi: 10.1080/00365549309169680. [DOI] [PubMed] [Google Scholar]
  4. Kremer J. M., Wilting J., Janssen L. H. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 1988 Mar;40(1):1–47. [PubMed] [Google Scholar]
  5. Kuikka A., Syrjänen J., Renkonen O. V., Valtonen V. V. Pneumococcal bacteraemia during a recent decade. J Infect. 1992 Mar;24(2):157–168. doi: 10.1016/0163-4453(92)92850-i. [DOI] [PubMed] [Google Scholar]
  6. Myburgh J., Nagel G. J., Petschel E. The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1993 Jun;31 (Suppl E):163–169. doi: 10.1093/jac/31.suppl_e.163. [DOI] [PubMed] [Google Scholar]
  7. Ortqvist A., Kalin M., Julander I., Mufson M. A. Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations--Huntington, WVa, and Stockholm, Sweden. Chest. 1993 Mar;103(3):710–716. doi: 10.1378/chest.103.3.710. [DOI] [PubMed] [Google Scholar]
  8. Peters D. H., Friedel H. A., McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992 Nov;44(5):750–799. doi: 10.2165/00003495-199244050-00007. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES